Journal of Psychosomatic Research
Volume 57, Issue 2 , Pages 155-158 , August 2004

Social support as a buffer in the relationship between treatment for depression and T-cell production of interferon gamma in patients with multiple sclerosis

  • David C. Mohr

      Affiliations

    • Corresponding Author InformationCorresponding author. Veterans Administration Medical Center, 4150 Clement St. (116-A), San Francisco, CA 94121, USA. Tel.: +1-415-221-4810x4636; fax: +1-415-751-2297
    • Departments of Psychiatry and Neurology, University of California, San Francisco, CA, USA
    • ,
  • Claude Genain

      Affiliations

    • Department of Neurology, University of California, San Francisco, CA, USA

Received 25 February 2003 ,Accepted 10 November 2003.

References 

  1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938–952
  2. Anderson P-B, Goodkin DE. Current pharmacologic treatment of multiple sclerosis symptoms. West J Med. 1996;165:313–317
  3. Schapiro RT. Symptom management in multiple sclerosis. Ann Neurol. 1994;36:S123–S129
  4. Thompson AJ. Multiple sclerosis: symptomatic treatment. J Neurol. 1996;243:559–565
  5. Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IM, Eisen K, et al. Depression and multiple sclerosis. Neurology. 1996;46(3):628–632
  6. Ackerman KD, Heyman R, Rabin BS, Anderson BP, Houck PR, Frank E, et al. Stressful life events precede exacerbations of multiple sclerosis. Psychosom Med. 2002;64(6):916–920
  7. Mohr DC, Goodkin DE, Bacchetti P, Boudewyn AC, Huang L, Marrietta P, et al. Psychological stress and the subsequent appearance of new brain MRI lesions in MS. Neurology. 2000;55(1):55–61
  8. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life as a predictor for change in disability in MS. Neurology. 2000;55(1):51–54
  9. Mohr DC, Goodkin DE, Islar J, Hauser SL, Genain CP. Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch Neurol. 2001;58(7):1081–1086
  10. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 1987;37:1097–1102
  11. Sarason IG, Sarason BR, Potter EH, Antoni MH. Life events, social support, and illness. Psychosom Med. 1985;47(2):156–163
  12. Esterling BA, Kiecolt-Glaser JK, Glaser R. Psychosocial modulation of cytokine-induced natural killer cell activity in older adults. Psychosom Med. 1996;58:264–272
  13. Cohen S, Doyle WJ, Skoner DP, Rabin BS, Gwaltney JM. Social ties and susceptibility to the common cold. J Am Med Assoc. 1997;277:1940–1944
  14. Mohr DC, Boudewyn AC, Goodkin DE, Bostrom A, Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive–expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol. 2001;69(6):942–949
  15. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227–231
  16. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907–911
  17. First MB, Spitzer RL, Gibbon M, Williams JB. Structured clinical interview for DSM-IV Axis I disorders—patient edition (SCID-I/P, Version 2.0). New York: New York State Psychiatric Institute; 1995;
  18. Spiegel D, Classen C. Group psychotherapy for cancer patients. New York: Basic Books; 2000;
  19. Richelson E. Synaptic effects of antidepressants. J Clin Psychopharmacol. 1996;16:1S–9S
  20. Beck AT, Ward CH, Medelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571
  21. Barrera M. A method for the assessment of social support networks in community survey research. Connections. 1983;3:8–13
  22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444–1452
  23. Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA. 1997;94:599–603
  24. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Increased CD56+ natural killer cells and related cytokines in major depression. Clin Immunol Immunopathol. 1996;78(1):83–85
  25. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Cytokine production and serum proteins in depression. Scand J Immunol. 1995;41(6):534–538
  26. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci. 2001;933:222–234
  27. Mohr DC, Goodkin DE. Treatment of depression in multiple sclerosis: review and meta-analysis. Clin Psychol Sci Pract. 1999;6:1–9
  28. Maes M, Song C, Lin AH, Bonaccorso S, Kenis G, De Jongh R, et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology. 1999;20(4):370–379
  29. Mohr DC, Cox D. Multiple sclerosis: empirical literature for the clinical health psychologist. J Clin Psychol. 2001;57(4):479–499

PII: S0022-3999(03)00601-9

doi: 10.1016/S0022-3999(03)00601-9

Journal of Psychosomatic Research
Volume 57, Issue 2 , Pages 155-158 , August 2004

Article Tools